Program in Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan.
Division of Gastroenterology, Taichung Veterans General Hospital, Taichung 407, Taiwan.
Mar Drugs. 2022 Jan 29;20(2):109. doi: 10.3390/md20020109.
Liver cancers, such as hepatocellular carcinoma (HCC), are a highly prevalent cause of cancer-related deaths. Current treatments to combat liver cancer are limited. (-)-Agelasidine A, a compound isolated from the methanol extract of , a sesquiterpene guanidine derived from sea sponge, has antibacterial activity. We demonstrated its anticancer capabilities by researching the associated mechanism of (-)-agelasidine A in human liver cancer cells. We found that (-)-agelasidine A significantly reduced viability in Hep3B and HepG2 cells, and we determined that apoptosis was involved in the (-)-agelasidine A-induced Hep3B cell deaths. (-)-Agelasidine A activated caspases 9, 8, and 3, as well as PARP. This effect was reversed by caspase inhibitors, suggesting caspase-mediated apoptosis in the (-)-agelasidine A-treated Hep3B cells. Moreover, the reduced mitochondrial membrane potential (MMP) and the release of cytochrome c indicated that the (-)-agelasidine A-mediated mitochondrial apoptosis was mechanistic. (-)-Agelasidine A also increased apoptosis-associated proteins (DR4, DR5, FAS), which are related to extrinsic pathways. These events were accompanied by an increase in Bim and Bax, proteins that promote apoptosis, and a decrease in the antiapoptotic protein, Bcl-2. Furthermore, our results presented that (-)-agelasidine A treatment bridged the intrinsic and extrinsic apoptotic pathways. Western blot analysis of Hep3B cells treated with (-)-agelasidine A showed that endoplasmic reticulum (ER) stress-related proteins (GRP78, phosphorylated PERK, phosphorylated eIF2α, ATF4, truncated ATF6, and CHOP) were upregulated. Moreover, 4-PBA, an ER stress inhibitor, could also abrogate (-)-agelasidine A-induced cell viability reduction, annexin V+ apoptosis, death receptor (DR4, DR5, FAS) expression, mitochondrial dysfunction, and cytochrome c release. In conclusion, by activating ER stress, (-)-agelasidine A induced the extrinsic and intrinsic apoptotic pathways of human HCC.
肝癌,如肝细胞癌(HCC),是癌症相关死亡的一个高度流行原因。目前对抗肝癌的治疗方法有限。(-)-Agelasidine A,一种从甲醇提取物中分离出来的化合物,是一种源自海绵的倍半萜胍,具有抗菌活性。我们通过研究(-)-agelasidine A 在人肝癌细胞中的相关机制来证明其抗癌能力。我们发现(-)-agelasidine A 可显著降低 Hep3B 和 HepG2 细胞的活力,并且我们确定凋亡参与了(-)-agelasidine A 诱导的 Hep3B 细胞死亡。(-)-Agelasidine A 激活了半胱天冬酶 9、8 和 3,以及 PARP。这种效应被半胱天冬酶抑制剂逆转,表明在(-)-agelasidine A 处理的 Hep3B 细胞中存在半胱天冬酶介导的凋亡。此外,减少的线粒体膜电位(MMP)和细胞色素 c 的释放表明,(-)-agelasidine A 介导的线粒体凋亡是机械性的。(-)-Agelasidine A 还增加了与外在途径相关的凋亡相关蛋白(DR4、DR5、FAS)。这些事件伴随着凋亡促进蛋白 Bim 和 Bax 的增加,以及抗凋亡蛋白 Bcl-2 的减少。此外,我们的结果表明,(-)-agelasidine A 处理桥接了内在和外在的凋亡途径。用(-)-agelasidine A 处理的 Hep3B 细胞的 Western blot 分析显示内质网(ER)应激相关蛋白(GRP78、磷酸化 PERK、磷酸化 eIF2α、ATF4、截断的 ATF6 和 CHOP)上调。此外,ER 应激抑制剂 4-PBA 也可以消除(-)-agelasidine A 诱导的细胞活力降低、膜联蛋白 V+凋亡、死亡受体(DR4、DR5、FAS)表达、线粒体功能障碍和细胞色素 c 释放。总之,通过激活 ER 应激,(-)-agelasidine A 诱导了人 HCC 的外在和内在凋亡途径。